{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=60",
    "query": {
      "condition": "Safety Study",
      "page": 60
    },
    "page_size": 10
  },
  "pagination": {
    "page": 60,
    "page_size": 10,
    "total_count": 33598,
    "total_pages": 3360,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=61&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=59&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T14:35:00.889Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01385189",
      "title": "Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hookworm Infection",
        "Hookworm Disease"
      ],
      "interventions": [
        {
          "name": "10 μg Na-GST-1/Alhydrogel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "30 μg Na-GST-1/Alhydrogel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "100 μg Na-GST-1/Alhydrogel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 40,
      "start_date": "2012-05",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2025-01-06",
      "last_synced_at": "2026-11-19T14:35:00.889Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01385189"
    },
    {
      "nct_id": "NCT01772368",
      "title": "Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Fp MDPI",
          "type": "DRUG"
        },
        {
          "name": "FS MDPI",
          "type": "DRUG"
        },
        {
          "name": "Advair Diskus",
          "type": "DRUG"
        },
        {
          "name": "Albuterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2013-01",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2017-06-12",
      "last_synced_at": "2026-11-19T14:35:00.889Z",
      "location_count": 10,
      "location_summary": "Denver, Colorado • North Dartmouth, Massachusetts • St Louis, Missouri + 7 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "North Dartmouth",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Skillman",
          "state": "New Jersey"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01772368"
    },
    {
      "nct_id": "NCT03064074",
      "title": "Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Osteogenesis Imperfecta"
      ],
      "interventions": [
        {
          "name": "Fresolimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2017-11-15",
      "completion_date": "2022-07-04",
      "has_results": true,
      "last_update_posted_date": "2024-12-04",
      "last_synced_at": "2026-11-19T14:35:00.889Z",
      "location_count": 2,
      "location_summary": "Portland, Oregon • Houston, Texas",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03064074"
    },
    {
      "nct_id": "NCT00001018",
      "title": "A Study of Letrazuril in the Treatment of AIDS-Related Diarrhea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cryptosporidiosis",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Letrazuril",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 32,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-11-19T14:35:00.889Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • New York, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001018"
    },
    {
      "nct_id": "NCT07611110",
      "title": "AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265])",
          "type": "DRUG"
        },
        {
          "name": "Cabazitaxel",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Apalutamide",
          "type": "DRUG"
        },
        {
          "name": "Darolutamide",
          "type": "DRUG"
        },
        {
          "name": "Deutenzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Radium-223",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 670,
      "start_date": "2026-05-04",
      "completion_date": "2030-06-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-11-19T14:35:00.889Z",
      "location_count": 28,
      "location_summary": "Dothan, Alabama • Phoenix, Arizona • Duarte, California + 24 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07611110"
    },
    {
      "nct_id": "NCT01488513",
      "title": "ABC294640 in Treating Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "sphingosine kinase-2 inhibitor ABC294640",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RedHill Biopharma Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2011-08",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2020-01-07",
      "last_synced_at": "2026-11-19T14:35:00.889Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01488513"
    },
    {
      "nct_id": "NCT03219320",
      "title": "Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Peripheral Neuropathy"
      ],
      "interventions": [
        {
          "name": "NYX-2925",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aptinyx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 301,
      "start_date": "2017-06-27",
      "completion_date": "2018-11-02",
      "has_results": true,
      "last_update_posted_date": "2020-06-09",
      "last_synced_at": "2026-11-19T14:35:00.889Z",
      "location_count": 35,
      "location_summary": "Phoenix, Arizona • Anaheim, California • Fresno, California + 29 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Norco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03219320"
    },
    {
      "nct_id": "NCT01255423",
      "title": "Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied 4 Times Daily in Subjects With Acute Ankle Sprain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ankle Sprain"
      ],
      "interventions": [
        {
          "name": "Diclofenac sodium topical gel 1%",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 206,
      "start_date": "2010-11",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2012-10-04",
      "last_synced_at": "2026-11-19T14:35:00.889Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Aventura, Florida • Hialeah, Florida + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Berlin",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01255423"
    },
    {
      "nct_id": "NCT05559359",
      "title": "A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atopic Dermatitis",
        "Eczema"
      ],
      "interventions": [
        {
          "name": "Lebrikizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Topical Corticosteroid (TCS)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Months to 17 Years"
      },
      "enrollment_count": 377,
      "start_date": "2022-10-18",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-11-19T14:35:00.889Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 18 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "North Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05559359"
    },
    {
      "nct_id": "NCT03473223",
      "title": "Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Coronary Syndrome"
      ],
      "interventions": [
        {
          "name": "Apolipoprotein A-I [human] (apoA-I)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18226,
      "start_date": "2018-03-21",
      "completion_date": "2023-11-17",
      "has_results": true,
      "last_update_posted_date": "2025-01-14",
      "last_synced_at": "2026-11-19T14:35:00.889Z",
      "location_count": 202,
      "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 175 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03473223"
    }
  ]
}